JPMorgan Chase & Co. Reaffirms Overweight Rating for Hikma Pharmaceuticals (LON:HIK)

JPMorgan Chase & Co. reissued their overweight rating on shares of Hikma Pharmaceuticals (LON:HIK – Free Report) in a report issued on Monday morning, Marketbeat.com reports. Several other research firms have also recently weighed in on HIK. Barclays boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,700 ($20.76) to GBX 1,800 ($21.99) […]

Related Keywords

United States ,America , ,Analyst Recommendations For Hikma Pharmaceuticals ,News Ratings For Hikma Pharmaceuticals Daily ,Hikma Pharmaceuticals ,Barclays ,Hikma Pharmaceuticals Price Performance ,Jpmorgan Chase Co ,Hikma Pharmaceuticals Cuts Dividend ,Citigroup ,Free Report ,Moderate Buy ,Get Free Report ,North America ,Middle East ,North Africa ,Hikma Pharmaceuticals Daily ,Lon Hik ,Zhik ,Medical ,Reiterated Rating ,Jpmorgan Chase Amp Co ,